(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193888 A1

(51) International Patent Classification:
C07D 23/14 (2006.01) *A61P 25/00* (2006.01)
A61K 31/50 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2025/019675

(22) International Filing Date:
13 March 2025 (13.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/565,212 14 March 2024 (14.03.2024) US

(71) Applicant: **VANQUA BIO, INC.** [US/US]; c/o Vanqua Bio, Inc., 1375 W Fulton Street, Suite 600, Chicago, IL 60607 (US).

(72) Inventors: **HUNT, Kevin**; c/o Vanqua Bio, Inc., 1375 W Fulton Street, Suite 600, Chicago, IL 60607 (US). **ZHENG, Jianbin**; 580 Green Bay Rd., Glencoe, IL 60022 (US). **SHEN, Sida**; c/o Vanqua Bio, Inc., 1375 W Fulton Street, Suite 600, Chicago, IL 60607 (US). **LEI, Zhiquan**; c/o Vanqua Bio, Inc., 1375 W. Fulton Street, Suite 600, Chicago, IL 60607 (US).

(74) Agent: **DUFFEY, Matthew, O.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2025/193888 A1

(54) Title: PYRIDAZINONE C5AR1 ANTAGONISTS AND USES THEREOF

(57) Abstract: Provided herein are compounds that modulate (e.g., antagonize) complement component 5a receptor 1 (C5aR1), a G protein-coupled receptor for C5a that is associated with autoimmune, inflammatory, and neurodegenerative disorders. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating C5aR1-related diseases and disorders with the compounds in a subject, by administering the compounds and/or compositions described herein.